Absci Shares Jump 37.8% on Positive ABS-201 Data and $100M Equity Raise

Absci Corporation (ABSI) shares surged 37.8% this week after the company reported encouraging interim Phase 1 data from its HEADLINE trial of ABS-201 for androgenetic alopecia. The data showed a favorable safety profile and an estimated half-life of at least 65 days, with the trial progressing to a multiple ascending dose stage. Concurrently, Absci completed a roughly $100 million follow-on equity offering backed by Eli Lilly & Company and other institutional investors, underscoring external confidence in the program.

Data Highlights

The Phase 1 interim results demonstrated favorable safety and pharmacokinetics, with a half-life of at least 65 days. The progression to multiple ascending doses marks a key milestone for the program.

Equity Offering

The $100 million equity offering included participation from Eli Lilly and other institutional investors, signaling strong support for Absci's pipeline.

What This Means for Investors

While these developments are positive, ABS-201 remains in early-stage trials. Investors should monitor upcoming clinical data to assess the full potential of the treatment.